Evidence map›Paper›PMID 33768236›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Hepatitis C Care Cascades for 3 Populations at High Risk: Low-income Trans Women, Young People Who Inject Drugs, and Men Who Have Sex With Men and Inject Drugs.

Shelley N Facente, Sheena Patel, Jennifer Hecht, Erin Wilson, Willi McFarland, Kimberly Page, Peter Vickerman, Hannah Fraser, Katie Burk, Meghan D Morris

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. The Urgent Need to Implement Point-of-Care RNA Testing for Hepatitis C Virus to Support Elimination.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Review
  7. Hepatitis A, B and C prevalence among transgender women and travestis in five Brazilian capitals between 2019-2021.Revista brasileira de epidemiologia = Brazilian journal of epidemiology · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shelley N FacenteSchool of Public Health, Division of Epidemiology and Biostatistics, University of California Berkeley, Berkeley, California, USA.
Sheena PatelDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Jennifer HechtSan Francisco AIDS Foundation, San Francisco, California, USA.
Erin WilsonSan Francisco Department of Public Health, San Francisco, California, USA.
Willi McFarlandDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Kimberly PageUniversity of New Mexico, Albuquerque, New Mexico, USA.
Peter VickermanPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Hannah FraserPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Katie BurkSan Francisco Department of Public Health, San Francisco, California, USA.
Meghan D MorrisDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.

Funding

Acute Hepatitis C Infection in Young InjectorsR01DA016017 · NIDA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PAGE, KIMBERLY · 2002 to 2018
$14.0M
The Transnational Cohort: global HIV epidemiology and prevention research for transwomen.R01MD010678 · NIMHD · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI MCFARLAND, WILLIAM, MEEK, ERIN CATHERINE · 2015 to 2019
$2.4M
Informing hepatitis C virus elimination strategies with epidemiological data from highest need populationsR21DA046809 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MORRIS, MEGHAN D · 2019 to 2020
$385k
NIDA NIH HHS R01 DA016017NIDA NIH HHS R21 DA046809NIMHD NIH HHS R01 MD010678
6 · The paper itself

Abstract

backgroundTo achieve elimination of hepatitis C virus (HCV) infection, limited resources can be best allocated through estimation of "care cascades" among groups disproportionately affected. In San Francisco and elsewhere, these groups include young (age ≤ 30 years) people who inject drugs (YPWID), men who have sex with men who inject drugs (MSM-IDU), and low-income trans women.

methodsWe developed cross-sectional HCV care cascades for YPWID, MSM-IDU, and trans women using diverse data sources. Population sizes were estimated using an inverse variance-weighted average of estimates from the peer-reviewed literature between 2013 and 2019. Proportions of past/current HCV infection, diagnosed infection, treatment initiation, and evidence of cure (sustained virologic response at 12 weeks posttreatment) were estimated from the literature using data from 7 programs and studies in San Francisco between 2015 and 2020.

resultsThe estimated number of YPWID in San Francisco was 3748; 58.4% had past/current HCV infection, of whom 66.4% were diagnosed with current infection, 9.1% had initiated treatment, and 50% had confirmed cure. The corresponding figures for the 8135 estimated MSM-IDU were: 29.4% with past/current HCV infection, 70.3% diagnosed with current infection, 28.4% initiated treatment, and 38.9% with confirmed cure. For the estimated 951 low-income trans women, 24.8% had past/current HCV infection, 68.9% were diagnosed with current infection, 56.5% initiated treatment, and 75.5% had confirmed cure.

conclusionsIn all 3 populations, diagnosis rates were relatively high; however, attention is needed to urgently increase treatment initiation in all groups, with a particular unmet need among YPWID.

Indexed as

Hepatitis CHIV InfectionsPharmaceutical PreparationsSexual and Gender MinoritiesSubstance Abuse, IntravenousAdolescentAdultCross-Sectional StudiesFemaleHepacivirusHomosexuality, MaleHumansMalePharmaceutical Preparationscare cascadehepatitis CMSMPWIDtransgender women

Identifiers

PMID33768236
PMCPMC8442786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.